An experiment with LNCap prostate cancer cells showed that SFN treatment reduced the expression of DNMT1 and 3b, resulting in a decrease in the global DNA methylation profile and cyclin D2 promoter methylation [59]. This evidence concerns the gene DNMT1 and Familial prostate cancer.